Issue 22, 2023

A multivariate metal–organic framework based pH-responsive dual-drug delivery system for chemotherapy and chemodynamic therapy

Abstract

Combination therapy has emerged as a promising strategy due to its synergistic therapeutic pathways that enhance anticancer efficacy and limit the emergence of drug resistance. In this work, MIL-88B type multivariate (MTV-1) nanocarriers based on a mixed linker (1,4-benzenedicarboxylic acid and biphenyl-4,4′-dicarboxylic acid) and metals (iron and cobalt) were synthesized. The presence of the distinct linkers modified the pore makeup of MTV-1 and facilitated the co-encapsulation of two anticancer drugs of varying molecular sizes: 5-fluorouracil (5-FU) and curcumin (CUR). The drug loading measurements on MTV-1@5-FU + CUR represented a loading capacity of 15.9 wt% for 5-FU and 9.3 wt% for CUR, respectively. They further exhibited a pH-responsive drug release pattern with higher concentrations of 5-FU and CUR released at pH 5.5 (simulating cancer microenvironment) compared to pH 7.4 (physiological environment). Moreover, we also demonstrated that MTV-1 MOFs, due to the presence of mixed valence metal ions, could exhibit peroxidase-like activity and catalyze H2O2 decomposition to produce ˙OH radicals for chemodynamic therapy. Cell cytotoxicity assays exhibited significant inhibitory effects of MTV-1@5-Fu + CUR against HepG2 cells with an IC50 of 78.7 μg mL−1. With dual-drug loading, pH-responsive release, and chemodynamic therapy, MTV-1 shows excellent potential for multifunctional anticancer treatment.

Graphical abstract: A multivariate metal–organic framework based pH-responsive dual-drug delivery system for chemotherapy and chemodynamic therapy

Supplementary files

Article information

Article type
Paper
Submitted
10 Jul 2023
Accepted
08 Oct 2023
First published
12 Oct 2023
This article is Open Access
Creative Commons BY-NC license

Mater. Adv., 2023,4, 5653-5667

A multivariate metal–organic framework based pH-responsive dual-drug delivery system for chemotherapy and chemodynamic therapy

M. U. Akbar, A. Akbar, U. A. K. Saddozai, M. I. U. Khan, M. Zaheer and M. Badar, Mater. Adv., 2023, 4, 5653 DOI: 10.1039/D3MA00389B

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements